Compare Stocks: LSTA, CNTX, GOSS, and FTH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTX Context Therapeutics	$0.52 +3.3%	$0.69	$0.43 ▼ $3.62	$48.04M	1.74	1.72 million shs	1.26 million shs
FTH Sensei Biotherapeutics	$32.34 +13.3%	$26.65	$7.21 ▼ $37.90	$835.67M	-0.25	276,479 shs	364,939 shs
GOSS Gossamer Bio	$0.15 -9.5%	$0.17	$0.11 ▼ $3.87	$36.19M	2.04	43.38 million shs	13.54 million shs
LSTA Lisata Therapeutics	$1.09 -3.5%	$2.64	$0.99 ▼ $5.07	$9.82M	0.88	128,470 shs	24,983 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTX Context Therapeutics	+3.26%	+8.04%	-17.04%	-75.79%	-25.30%
FTH Sensei Biotherapeutics	+13.27%	+32.60%	+2.76%	+3,233,999,900.00%	+3,233,999,900.00%
GOSS Gossamer Bio	-9.45%	-13.37%	-4.64%	-54.65%	-92.17%
LSTA Lisata Therapeutics	-3.54%	+2.83%	-70.93%	-65.62%	-59.48%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTX Context Therapeutics	$0.52 +3.3%	$0.69	$0.43 ▼ $3.62	$48.04M	1.74	1.72 million shs	1.26 million shs
FTH Sensei Biotherapeutics	$32.34 +13.3%	$26.65	$7.21 ▼ $37.90	$835.67M	-0.25	276,479 shs	364,939 shs
GOSS Gossamer Bio	$0.15 -9.5%	$0.17	$0.11 ▼ $3.87	$36.19M	2.04	43.38 million shs	13.54 million shs
LSTA Lisata Therapeutics	$1.09 -3.5%	$2.64	$0.99 ▼ $5.07	$9.82M	0.88	128,470 shs	24,983 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTX Context Therapeutics	+3.26%	+8.04%	-17.04%	-75.79%	-25.30%
FTH Sensei Biotherapeutics	+13.27%	+32.60%	+2.76%	+3,233,999,900.00%	+3,233,999,900.00%
GOSS Gossamer Bio	-9.45%	-13.37%	-4.64%	-54.65%	-92.17%
LSTA Lisata Therapeutics	-3.54%	+2.83%	-70.93%	-65.62%	-59.48%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTX Context Therapeutics	2.70	Moderate Buy	$6.17	1,079.32% Upside
FTH Sensei Biotherapeutics	2.83	Moderate Buy	$54.90	69.76% Upside
GOSS Gossamer Bio	2.22	Hold	$3.20	1,975.23% Upside
LSTA Lisata Therapeutics	1.67	Reduce	$15.00	1,276.15% Upside

Current Analyst Ratings Breakdown

Latest LSTA, CNTX, GOSS, and FTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	FTH Sensei Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$60.00
8/6/2026	CNTX Context Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/6/2026	CNTX Context Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/6/2026	CNTX Context Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/4/2026	FTH Sensei Biotherapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$55.00
7/31/2026	LSTA Lisata Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/31/2026	FTH Sensei Biotherapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$56.00
7/28/2026	FTH Sensei Biotherapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$60.00
7/28/2026	GOSS Gossamer Bio	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$1.00
7/27/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/20/2026	FTH Sensei Biotherapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$51.00

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	$0.42 per share	N/A
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	$6.69 per share	N/A
GOSS Gossamer Bio	$48.47M	0.75	N/A	N/A	($0.53) per share	-0.29
LSTA Lisata Therapeutics	$100K	98.22	N/A	N/A	$0.89 per share	1.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTX Context Therapeutics	-$36.12M	-$0.48	N/A	N/A	N/A	N/A	-82.06%	-72.74%	N/A
FTH Sensei Biotherapeutics	-$21.08M	-$141.65	N/A	N/A	N/A	N/A	-1,012.17%	-175.69%	N/A
GOSS Gossamer Bio	-$170.37M	-$0.70	N/A	N/A	N/A	-235.00%	N/A	-96.70%	N/A
LSTA Lisata Therapeutics	-$16.59M	-$1.86	N/A	N/A	N/A	N/A	-116.08%	-90.55%	N/A

Latest LSTA, CNTX, GOSS, and FTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	GOSS Gossamer Bio	-$0.1234	-$0.08	+$0.0434	-$0.08	$3.63 million	$9.24 million
8/5/2026	Q2 2026	CNTX Context Therapeutics	-$0.0921	-$0.15	-$0.0579	-$0.15	N/A	N/A
5/15/2026	Q1 2026	FTH Sensei Biotherapeutics	N/A	-$131.45	N/A	-$131.45	N/A	N/A
5/15/2026	Q4 2025	FTH Sensei Biotherapeutics	-$0.62	-$131.45	-$130.83	-$131.45	N/A	N/A
5/15/2026	Q1 2026	GOSS Gossamer Bio	-$0.17	-$0.20	-$0.03	-$0.20	$4.67 million	$16.96 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	N/A
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
LSTA Lisata Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTX Context Therapeutics	N/A	5.81	5.81
FTH Sensei Biotherapeutics	N/A	19.69	19.69
GOSS Gossamer Bio	N/A	2.20	2.20
LSTA Lisata Therapeutics	N/A	3.69	4.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTX Context Therapeutics	14.03%
FTH Sensei Biotherapeutics	10.50%
GOSS Gossamer Bio	81.23%
LSTA Lisata Therapeutics	8.94%

Insider Ownership

Company	Insider Ownership
CNTX Context Therapeutics	4.80%
FTH Sensei Biotherapeutics	7.00%
GOSS Gossamer Bio	3.74%
LSTA Lisata Therapeutics	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTX Context Therapeutics	7	91.88 million	87.47 million	Not Optionable
FTH Sensei Biotherapeutics	40	25.84 million	24.03 million	Not Optionable
GOSS Gossamer Bio	180	234.70 million	225.92 million	Optionable
LSTA Lisata Therapeutics	30	9.01 million	8.15 million	Not Optionable

LSTA, CNTX, GOSS, and FTH Headlines

Recent News About These Companies

Lisata Therapeutics moves forward with legal action following Kuva merger termination

August 4, 2026 | proactiveinvestors.com

Lisata Therapeutics moves forward with legal action following Kuva merger termination

August 4, 2026 | proactiveinvestors.com

Lisata Therapeutics Files Suit Against Kuva Labs, Reviews Strategic Alternatives and Cuts Workforce to Preserve Cash

August 4, 2026 | quiverquant.comQ

Lisata Therapeutics Provides Update Following Termination of Merger Agreement

August 4, 2026 | globenewswire.com

Lisata Therapeutics stock falls after hours: Here's why

July 23, 2026 | msn.com

Lisata Therapeutics Extends Merger Timeline with Kuva Labs

July 17, 2026 | tipranks.com

Johnson Fistel Investigates Lisata Therapeutics, Inc. (LSTA) After Disclosures Concerning Acquisition Financing

June 26, 2026 | globenewswire.com

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA)

June 15, 2026 | newsfilecorp.comN

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA)

June 15, 2026 | newsfilecorp.comN

Lisata Therapeutics, Inc.: Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.

June 10, 2026 | finanznachrichten.de

Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share

June 10, 2026 | proactiveinvestors.com

Lisata Therapeutics Announces Tender Offer from Kuva Acquisition Corp at $4.00 per Share Plus Contingent Value Rights

June 10, 2026 | quiverquant.comQ

Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.

June 10, 2026 | globenewswire.com

Kuva and Lisata Therapeutics Tender Offer Update

June 1, 2026 | tennessean.comT

HC Wainwright & Co. downgrades Lisata Therapeutics (LSTA)

May 16, 2026 | msn.com

Lisata Therapeutics Amends Kuva Labs Merger Agreement Timeline

May 9, 2026 | theglobeandmail.com

Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders

May 4, 2026 | globenewswire.com

Lisata Therapeutics Delays Tender Offer Launch in Merger

April 3, 2026 | tipranks.com

Leading Financial Trade Associations, Led by LSTA, Submit Amicus Brief in Support of Defendant Lenders in Antitrust Case Filed by Optumum Communications

March 26, 2026 | businesswire.com

Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances

March 10, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LSTA, CNTX, GOSS, and FTH Company Descriptions

Context Therapeutics NASDAQ:CNTX

$0.52 +0.02 (+3.26%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$0.52 0.00 (-0.94%)

As of 08/14/2026 07:25 PM Eastern

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Sensei Biotherapeutics NASDAQ:FTH

$32.34 +3.79 (+13.27%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$32.53 +0.19 (+0.60%)

As of 08/14/2026 07:34 PM Eastern

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Gossamer Bio NASDAQ:GOSS

$0.15 -0.02 (-9.45%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$0.16 +0.00 (+1.17%)

As of 08/14/2026 07:59 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Lisata Therapeutics NASDAQ:LSTA

$1.09 -0.04 (-3.54%)

Closing price 08/14/2026 03:59 PM Eastern

Extended Trading

$1.14 +0.05 (+4.95%)

As of 08/14/2026 07:18 PM Eastern

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LSTA, CNTX, GOSS, and FTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LSTA, CNTX, GOSS, and FTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LSTA, CNTX, GOSS, and FTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LSTA, CNTX, GOSS, and FTH Company Descriptions

Context Therapeutics NASDAQ:CNTX

Sensei Biotherapeutics NASDAQ:FTH

Gossamer Bio NASDAQ:GOSS

Lisata Therapeutics NASDAQ:LSTA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LSTA, CNTX, GOSS, and FTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LSTA, CNTX, GOSS, and FTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LSTA, CNTX, GOSS, and FTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LSTA, CNTX, GOSS, and FTH Company Descriptions

Context Therapeutics NASDAQ:CNTX

Sensei Biotherapeutics NASDAQ:FTH

Gossamer Bio NASDAQ:GOSS

Lisata Therapeutics NASDAQ:LSTA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools